Kininogen-1 derived peptides for in vivo half-life extension of protein drugs

摘要

Recombinant protein drugs include the parent protein drug conjugated to a modified kininogen-1 peptide. The modified kininogen-1 peptide has the sequence of SEQ ID NO: 2 and a homolog having 80% or more sequence identity. The parent protein drug is a bispecific antibody having a first target domain linked to a second target domain by a bridging domain. The modified kininogen-1 peptide is fused between a first targeting domain and a bridging domain or between a bridging domain and a second targeting domain. A method for increasing the serum half-life of a protein drug involves constructing a fusion protein comprising the protein drug conjugated to a modified kininogen-1 peptide.